Physician profile
Jose Ros
NPI 1356301634
$6,577.39
in general payments reported to CMS, 2019-2025
39 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $631 · 2021: $757 · 2022: $703 · 2023: $1,207 · 2024: $1,378 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,791.31 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.59 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $944.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $816.15 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.54 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $391.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $307.23 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Pfizer INC. | $251.73 | 2019-2025 | |
| Abbvie INC. | $247.45 | 2023-2025 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $243.51 | 2019-2024 | |
| Amgen INC. | $237.98 | 2019-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $222.04 | 2019-2023 | |
| Exact Sciences Corporation | $124.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Averitas Pharma INC. | $111.35 | 2023-2025 | Qutenza |
| Bausch Health US, LLC | $110.83 | 2019-2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $87.71 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.47 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $79.92 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $75.92 | 2019-2025 | Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $69.44 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $53.96 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Upsher-Smith Laboratories LLC | $52.83 | 2021 | |
| Idorsia Pharmaceuticals US INC | $51.96 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $51.73 | 2023-2024 | Watchman Flx, Watchman Access System |
| Corcept Therapeutics | $46.50 | 2025 | Korlym |
| Dexcom, INC. | $44.98 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $43.48 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $34.90 | 2024 | Veozah |
| Globus Medical, INC. | $29.90 | 2025 | Senza |
| Arbor Pharmaceuticals, INC. | $29.59 | 2019-2020 | |
| Esperion Therapeutics, INC. | $28.43 | 2020-2023 | Nexletol |
| Seqirus USA INC | $24.57 | 2025 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $22.82 | 2024 | Inspire |
| Azurity Pharmaceuticals, INC. | $20.09 | 2023 | Adthyza |
| Paratek Pharmaceuticals, INC. | $18.36 | 2024 | Nuzyra |
| Medtronic, INC. | $17.06 | 2023 | Intellis Adaptivestim |
| Vifor Pharma, INC. | $16.69 | 2023 | Veltassa |
| Intra-Sana Laboratories | $15.93 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $15.83 | 2022 | |
| Medtronic USA, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.